期刊文献+

核苷(酸)类似物抗乙型肝炎病毒治疗耐药的处理 被引量:8

原文传递
导出
摘要 抗乙型肝炎病毒治疗是乙型病毒性肝炎的关键治疗措施。抗乙肝抗病毒药物主要有干扰素和核苷(酸)类似物两大类。核苷(酸)类药物(NAs)由于其抑制病毒复制能力强,使用方便,不良反应较小等优点,在临床上广泛使用。目前在我国正式上市的抗HBV核苷(酸)类似物共有4种:拉米夫定(LAM)、阿德福韦酯(ADV)、恩替卡韦(ETV)和替比夫定(LdT),还有即将上市的替诺福韦酯(TDF)等。
作者 李玉芳
出处 《临床内科杂志》 CAS 2013年第11期734-736,共3页 Journal of Clinical Internal Medicine
  • 相关文献

参考文献20

  • 1参加乙型肝炎病毒耐药讨沈会专家.核苷和核苷酸类药物治疗慢性乙型肝炎的耐药及其管理[J].中华肝脏病杂志,2013,21(1):15-22. 被引量:49
  • 2Locamini S.Primary resistance,multidrug resistance,and cross-resistance pathways in HBV as a consequence of treatment failure.Hepatol Int,2008,2:147-151. 被引量:1
  • 3Gish R,Jia JD,Locarnini S,et al.Selection of chronic hepatitis B therapy with high barrier to resistance.Lancet Infect Dis,2012,12:341-353. 被引量:1
  • 4Lok AS,Zoulim F,Locamini S,et al.Antiviral drug-resistant HBV:standardization of nomenclature and assays and recommendations for management.Hepatology,2007,46:254-265. 被引量:1
  • 5Locamini S.Molecular virology and the development of resistant mutants:implications for therapy.Semin Liver Dis,2005,25 (Suppl1):S9-19. 被引量:1
  • 6Kim SS,Cheong JY,Cho SW.Current nucleos(t) icle analogue therapy for chronic Hepatitis B.GutLiver,2011,5:278-287. 被引量:1
  • 7Tenney DJ,Levine SM,Rose RE,et al.Clinical emergence of entecavirresistant hepatitis B virus requires additional substitutions in virus already resistant to Lamivudine.Antimicrob Agents Chemother,2004,48:3498-3507. 被引量:1
  • 8Villet S,Ollivet A,Pichoud C,et al.Stepwise process for the development of entecavir-resistance in a chronic hepatitis B virus infected patient.J Hepatol,2007,46:531-538. 被引量:1
  • 9Reijnders JG,Deterding K,Petersen J,et al.Antiviral effcct of entecavir in chronic hepatitis B:influence of prior exposure to nucleos(t) ide analogucs.J Hepatol,2010,52:493-500. 被引量:1
  • 10Villet S,Piehoud C,Billioud G,et al.Impact of hepatitisB virus RtAl81 v/r mutantson hepatitisB treatment failure.J Hepatol,2008,48:747-755. 被引量:1

二级参考文献58

共引文献3271

同被引文献74

  • 1卢明辉.核苷类药物抗病毒耐药分析[J].医学信息(医学与计算机应用),2014,0(11):217-217. 被引量:1
  • 2Fung SK,Chae HB,Fontana RJ.慢性乙肝患者阿德福韦治疗的病毒学应答和耐药性[J].中国处方药,2006,5(3):22-22. 被引量:63
  • 3王宇明,陈耀凯,张大志,雷秉钧,陆志檬,尹有宽,俞云松.阿德福韦酯治疗拉米夫定耐药慢性乙型肝炎的临床研究[J].中华肝脏病杂志,2006,14(11):803-805. 被引量:84
  • 4Bartholomeusz A, Locarnini SA. Antiviral drug resistance : clinical con- sequences and molecular aspects [ J ]. Semin Liver Dis, 2006,26 ( 2 ) : 162-170. 被引量:1
  • 5Borroto-Esoda K, Miller MD, Arterburn S. Pooled analysis of amino acid changes in the HBV polymerase in patients from four major adefovir dipivoxil elinieal trials[ J]. J Hepatol,2007,47(4) :492-498. 被引量:1
  • 6Loearnini S. Primary resistance, multidrug resistanee, and cross-resist- ance pathways in HBV as a consequence of treatment failure [ J ]. Hepa- tol Inter,2008,2(2) :147-151. 被引量:1
  • 7Walsh AW, Langley DR, Colonno R J, et al. Meehanistie characterization and molecular modeling of hepatitis B virus polymerase resistance to en- tecavir [ J]. PLoS One. 2010.5 ( 2 ) : e9195. 被引量:1
  • 8European Association for the Study of the Liver(EASL)2012EASL Clinical Practice Guidelines:Management of chronic hepatitis B virus infection[J].J Hepatol,2012,57(1):167. 被引量:1
  • 9American Association for the Study of Liver Diseases(AASLD)Chronic Hepatitis B:Update2009Hepatology[J].Hepatology,2009,50(3):661. 被引量:1
  • 10Sheldon J,Camino N,Rodes B,et al.Selection of hepatitis B virus polymerase mutations in HIV-coinfected patients treatedwith tenofovir[J].Antivir Ther,2005,10(6):727. 被引量:1

引证文献8

二级引证文献48

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部